How is superior vena cava obstruction treated?
SVCS due to thrombus around a central venous catheter may be treated with thrombolytics or anticoagulants. Removal of the catheter, if possible, is another option (in combination with anticoagulation). Surgical bypass of the SVC may be a useful way to palliate symptoms in carefully selected patients with SVCS.
Which treatment should be provided to reduce the symptoms of superior vena cava SVC syndrome?
Treatment will depend on the type of cancer involved and may include a combination of chemotherapy and radiation. In cases where superior vena cava syndrome is caused by a blood clot, blood thinners may be prescribed. A stent may also be used to open up the vein. In rare cases, bypass surgery may be performed.
What causes a blood clot in the superior vena cava?
Superior vena cava (SVC) syndrome occurs due to mechanical obstruction of blood flow to the right atrium of the heart through SVC. This occurs mostly due to compression or invasion of SVC by mediastinal masses (e.g. tumour, enlarged lymph node) and less commonly due to thrombosis.
Can you live without a superior vena cava?
Complete absence of both SVC is very rare and usually accompanied by other congenital anomalies of the heart, including cardiac conduction system, or thoracic duct system.
How do you treat SVC compression?
When SVCS is due to thrombus around a central venous catheter, patients may be treated with thrombolytics (eg, streptokinase, urokinase, or recombinant tissue-type plasminogen activator) or anticoagulants (eg, heparin or oral anticoagulants).
What happens if superior vena cava is blocked?
Superior vena cava syndrome (SVCS) is a group of symptoms that occur when there is pressure on the superior vena cava, or it is partially blocked and blood can’t flow back to the heart normally. This causes more pressure in the veins and face, which leads to a buildup of fluid or swelling.
Can you survive superior vena cava syndrome?
Survival in patients with SVCS depends mainly on the course of the underlying disease. No mortality, per se, results directly from mild venous congestion. In patients with benign SVCS, life expectancy is unchanged. If SVCS is secondary to a malignant process, patient survival correlates with tumor histology.